⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063023 | 0.82 | CYP11B2 (0.41) | — | |
| SCHEMBL10733555 | 0.76 | AOC3 (0.42) | — | |
| SCHEMBL16754379 | 0.76 | CDK2 (0.40) | — | |
| SCHEMBL14300700 | 0.76 | CDK2 (0.41) | — | |
| SCHEMBL421693 | 0.73 | — | — | |
| SCHEMBL231933 | 0.73 | — | — | |
| SCHEMBL9458864 | 0.73 | — | — | |
| SCHEMBL27808820 | 0.73 | CDK2 (0.38) | — | |
| SCHEMBL1604498 | 0.73 | — | — | |
| SCHEMBL25403941 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | claimed |
| EP-4219500-A1 | CONDENSED HETEROCYCLIC COMPOUND | Nissan Chemical Corporation (JP) | 2023-08-02 | — | — | EP | claimed |
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | claimed |
| EP-1453831-A1 | 1H-PYRROLO(3,2-B)PYRIDINE-3-CARBOXYLIC ACID AMIDES | Neurogen Corporation (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | claimed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | claimed |
| WO-2003044018-A1 | 1H-PYRROLO[3,2-B]PYRIDINE-3-CARBOXYLIC ACID AMIDES | NEUROGEN CORPORATION (US) | 2003-05-30 | — | — | WO | claimed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-0111160-A1 | Process for the preparation of 2-halogen and 2-cyano pyrazines | BASF Aktiengesellschaft (DE) | 1984-06-20 | — | — | EP | disclosed |
| US-4343802-A | ADRENERGIC BLOCKING, ANTIARRYHYTHMIA, AND CARDIOTONIC AGENTS | MERCK, SHARP & DOHME (I.A.) CORP. (US) | 1982-08-10 | — | — | US | disclosed |
| US-4193995-A | B-ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORP. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4042586-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1977-08-16 | — | — | US | disclosed |
| US-3946009-A | ADRENERGIC BLOCKING AGENTS | MERCK SHARP & DOHME (I.A.) CORPORATION (US) | 1976-03-23 | — | — | US | disclosed |